Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 100Carcinoma, Non-Small-Cell Lung 48Neoplasms 34Urinary Bladder Neoplasms 25Lung Neoplasms 25Cholangiocarcinoma 23Breast Neoplasms 22Neoplasm Metastasis 21Ovarian Neoplasms 18Lymphoma, Non-Hodgkin 13Lymphoma 13Recurrence 12Lymphoma, Large B-Cell, Diffuse 11Biliary Tract Neoplasms 11Sarcoma 10Carcinoma, Transitional Cell 9Hodgkin Disease 8Gallbladder Neoplasms 8Fallopian Tube Neoplasms 8Adenocarcinoma 8Bile Duct Neoplasms 7Colorectal Neoplasms 6Triple Negative Breast Neoplasms 5Lymphoma, Follicular 5Liver Neoplasms 5Head and Neck Neoplasms 5Carcinoma, Renal Cell 5Adenocarcinoma of Lung 5Uterine Cervical Neoplasms 4Small Cell Lung Carcinoma 4

Interventions

regorafenib 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Metastatic Pancreatic Adenocarcinoma × Gemcitabine × Clear all
NCT02383433 2023-10-23

Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

Case Comprehensive Cancer Center

Phase 2 Terminated
2 enrolled 8 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡